^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Flynpovi (eflornithine/sulindac)

    i
    Other names: CPP-1X/sul, CPP-1X/sulindac, CPP1-x/sulindac, sulindac/CPP-1X, DFMO/sulindac, TP 09
    Company:
    Panbela Therap
    Drug class:
    Ornithine decarboxylase inhibitor, COX inhibitor, SSAT activator
    Related drugs:
    1year
    PACES: S0820, Adenoma and Second Primary Prevention Trial (clinicaltrials.gov)
    P3, N=354, Active, not recruiting, SWOG Cancer Research Network | Recruiting --> Active, not recruiting | N=1340 --> 354
    Enrollment closed • Enrollment change
    |
    Flynpovi (eflornithine/sulindac)
    over1year
    Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats. (PubMed, Cancers (Basel))
    In addition, enhancement of p21, Bax, and caspases; downregulation of Ki-67, VEGF, and β-catenin; and modulation of iNOS, COX-2, and ODC activities in colonic tumors were observed. These observations show that a lower-dose of DFMO and Sulindac significantly enhanced CRC chemopreventive efficacy when compared to NO-Sulindac alone, and the combination of DFMO and NO-Sulindac was modestly efficacious as compared to DFMO alone.
    Preclinical • Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    Flynpovi (eflornithine/sulindac)